Sinopharm Group Co. Ltd (X2S) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has a cash flow conversion efficiency ratio of -0.023x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.63 Billion ≈ $-3.08 Billion USD) by net assets (€113.11 Billion ≈ $132.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinopharm Group Co. Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sinopharm Group Co. Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Sinopharm Group Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinopharm Group Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shufersal
TA:SAE
|
0.200x |
|
NBTM New Materials Group Co Ltd
SHG:600114
|
0.081x |
|
Turkiye Sigorta AS
IS:TURSG
|
0.086x |
|
Jumbo S.A.
AT:BELA
|
0.023x |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
0.047x |
|
Wienerberger AG
VI:WIE
|
0.081x |
|
Shanghai Lingang Holdings Co Ltd A
SHG:600848
|
-0.002x |
|
Iskenderun Demir ve Celik AS
IS:ISDMR
|
0.152x |
Annual Cash Flow Conversion Efficiency for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Sinopharm Group Co. Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Sinopharm Group Co. Ltd (X2S) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €126.69 Billion ≈ $148.11 Billion |
€11.55 Billion ≈ $13.50 Billion |
0.091x | -36.15% |
| 2023-12-31 | €120.32 Billion ≈ $140.67 Billion |
€17.17 Billion ≈ $20.08 Billion |
0.143x | -25.06% |
| 2022-12-31 | €110.07 Billion ≈ $128.68 Billion |
€20.96 Billion ≈ $24.51 Billion |
0.190x | +103.91% |
| 2021-12-31 | €99.65 Billion ≈ $116.51 Billion |
€9.31 Billion ≈ $10.88 Billion |
0.093x | -24.68% |
| 2020-12-31 | €89.95 Billion ≈ $105.16 Billion |
€11.15 Billion ≈ $13.04 Billion |
0.124x | -49.19% |
| 2019-12-31 | €76.94 Billion ≈ $89.95 Billion |
€18.78 Billion ≈ $21.95 Billion |
0.244x | +356.05% |
| 2018-12-31 | €68.28 Billion ≈ $79.82 Billion |
€3.65 Billion ≈ $4.27 Billion |
0.054x | -14.49% |
| 2017-12-31 | €51.27 Billion ≈ $59.94 Billion |
€3.21 Billion ≈ $3.75 Billion |
0.063x | -69.90% |
| 2016-12-31 | €44.53 Billion ≈ $52.06 Billion |
€9.26 Billion ≈ $10.82 Billion |
0.208x | -36.64% |
| 2015-12-31 | €40.88 Billion ≈ $47.79 Billion |
€13.41 Billion ≈ $15.68 Billion |
0.328x | +114.12% |
| 2014-12-31 | €36.29 Billion ≈ $42.43 Billion |
€5.56 Billion ≈ $6.50 Billion |
0.153x | -11.27% |
| 2013-12-31 | €28.61 Billion ≈ $33.45 Billion |
€4.94 Billion ≈ $5.78 Billion |
0.173x | -- |
About Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more